These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38317590)

  • 1. Comparison of IL-2-antibody to IL-2-Fc with or without stereotactic radiation therapy in CEA immunocompetent mice with CEA positive tumors.
    Williams L; Li L; Yazaki PJ; Wong P; Hong T; Poku EK; Hui S; Ghimire H; Shively JE; Kujawski M
    Cancer Med; 2024 Feb; 13(3):e6909. PubMed ID: 38317590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation.
    Kujawski M; Sherman M; Hui S; Zuro D; Lee WH; Yazaki P; Sherman A; Szpikowska B; Chea J; Lasiewski D; Poku K; Li H; Colcher D; Wong J; Shively JE
    Oncoimmunology; 2020; 9(1):1724052. PubMed ID: 32117587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of IL-2-Fc-antibody conjugates by click chemistry.
    Williams L; Li L; Yazaki PJ; Wong P; Miller A; Hong T; Poku EK; Bhattacharya S; Shively JE; Kujawski M
    Biotechnol J; 2023 Sep; 18(9):e2300115. PubMed ID: 37300381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
    Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
    Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Tumor Responses with Sequential Targeted α-Particles Followed by Interleukin 2 Immunocytokine Therapies in Treatment of CEA-Positive Breast and Colon Tumors in CEA Transgenic Mice.
    Minnix M; Kujawski M; Poku E; Yazaki PJ; Wong JY; Shively JE
    J Nucl Med; 2022 Dec; 63(12):1859-1864. PubMed ID: 35772959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
    Klein C; Waldhauer I; Nicolini VG; Freimoser-Grundschober A; Nayak T; Vugts DJ; Dunn C; Bolijn M; Benz J; Stihle M; Lang S; Roemmele M; Hofer T; van Puijenbroek E; Wittig D; Moser S; Ast O; Brünker P; Gorr IH; Neumann S; de Vera Mudry MC; Hinton H; Crameri F; Saro J; Evers S; Gerdes C; Bacac M; van Dongen G; Moessner E; Umaña P
    Oncoimmunology; 2017; 6(3):e1277306. PubMed ID: 28405498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
    Gillies SD; Lan Y; Williams S; Carr F; Forman S; Raubitschek A; Lo KM
    Blood; 2005 May; 105(10):3972-8. PubMed ID: 15692062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
    Kim PS; Kwilas AR; Xu W; Alter S; Jeng EK; Wong HC; Schlom J; Hodge JW
    Oncotarget; 2016 Mar; 7(13):16130-45. PubMed ID: 26910920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PET-Tracer
    Griessinger CM; Olafsen T; Mascioni A; Jiang ZK; Zamilpa C; Jia F; Torgov M; Romero JM; Marchioni F; Satpayev D; Lee C; Zhang G; Nayak TK; Pincha M; Amann M; Mohan PLB; Richard M; Nicolini VG; Sam J; Claus C; Ferrara C; Brünker P; Bacac M; Umana P; Rüttinger D; Wilson IA; Gudas J; Klein C; Tessier JJL
    Cancer Res; 2020 Jul; 80(13):2903-2913. PubMed ID: 32409308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine combined with nonlytic interleukin 2/Fc fusion protein improves immune response to hepatitis B vaccination in a mouse skin transplantation model.
    Li Z; Zhang D; Gao J; Li WX; Zhu JY
    Transplant Proc; 2013; 45(6):2559-64. PubMed ID: 23953581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities.
    Liu Y; Wang Y; Xing J; Li Y; Liu J; Wang Z
    Drug Des Devel Ther; 2018; 12():2645-2654. PubMed ID: 30214153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
    Vazquez-Lombardi R; Loetsch C; Zinkl D; Jackson J; Schofield P; Deenick EK; King C; Phan TG; Webster KE; Sprent J; Christ D
    Nat Commun; 2017 May; 8():15373. PubMed ID: 28497796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.
    Song K; Chang Y; Prud'homme GJ
    Gene Ther; 2000 Sep; 7(18):1527-35. PubMed ID: 11021590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
    Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
    Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP; Schlom J; Kantor JA; Greiner JW
    Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.